Symbols

GRCE

Grace Therapeutics·NASDAQ

--(--)

7.66 / 10

Outperform

No analyst consensus is available (ana_eval -1). Fund‑flow sentiment is good (7.66) with overall inflow ratio ~0.44, though all size‑segment trends are negative. The strong flow score offsets the lack of analyst guidance, supporting a cautiously optimistic outlook.

Fund Flow Rating

What is the market sentiment for GRCE?

GRCE holds a Neutral analyst rating, with 0% of experts assigning a Hold grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 7.66/10 (Outperform).